Prostate cancer (PCa) remains a leading cause of cancer-related deaths in American men and treatment options for metastatic PCa are limited. There is a critical need to identify new mechanisms that contribute to PCa progression, that distinguish benign from lethal disease, and that have potential for therapeutic targeting.
The prognosis of prostate cancer (PC) is generally favorable but the incidence of metastases is relatively high after the treatment of the primary tumor, especially in high-risk patients. Fractionated stereotactic body radiotherapy (SBRT) or single fraction stereotactic body radiosurgery (SRS) are emerging treatment options in this setting.
Transurethral resection of the urinary bladder (TURB) is the standard intervention in the diagnostic workup and treatment of non-muscle invasive bladder cancer. In order to minimize cancer recurrence and potential complications, continuous technical development of TURB is of high clinical interest.
Follow-up for non-muscle invasive bladder cancer (NMIBC) is a challenge for urologists that has not been finally resolved. The intensity of follow-up is based on the recurrence and progression behavior of the tumor as well as the patient’s individual situation.
Zachary Klaassen: Hello, and thank you for joining us today for this NCCN Clinical Practice Guidelines in Oncology brought to you by Uro Today. We are looking at prostate cancer version 2.2021, and specifically the risk stratification for clinically localized disease. My name is Zach Klassen, I’m an Assistant Professor in the Division of Urology […]
The urological community has the obligation to grasp every means to reduce mortality from urological cancers. Prostate cancer is the most frequent male cancer and is the second most lethal cancer in men in an increasing number of countries. The disease has a particularly long palliative period with a huge impact on quality of life […]
Despite the proven benefit of prostate cancer screening by the European Randomized Study of Screening for Prostate Cancer (ERSPC),1 policymakers do not recommend prostate cancer screening because of its related overdiagnosis: a fair point when it comes to a purely PSA-based screening algorithm as was applied within the ERSPC. However, the use of PSA, as the […]
This prospective registry study evaluated the feasibility of stereotactic magnetic resonance imaging (MRI)-guided radiation therapy for the local treatment of isolated prostate cancer recurrence within the gland or prostate bed after primary radiation therapy.
Penile squamous cell carcinoma (pSCC) is a rare disease in developed countries. pSCC causes a severe health problem and social burden in developing countries. We reported a 49-year-old male recurrent pSCC patient with medium PD-L1 expression and low TMB.
On the basis of the discussion of the current state of research on relevant topics of non-muscle-invasive bladder cancer (NMIBC) among a group of experts of the Spanish Oncology Genitourinary (SOGUG) Working Group, recommendations were proposed to overcome the challenges posed by the management of NMIBC in clinical practice.
